Physician profile
Nitin Jain
NPI 1750478392
$11,773.07
in general payments reported to CMS, 2019-2025
38 companies · $5,492 in 2025
The $5,492 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $807 · 2021: $1,128 · 2022: $811 · 2023: $1,420 · 2024: $1,741 · 2025: $5,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,053 · Consulting Fee: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,052.88 |
| Consulting Fee | $3,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $3,850.00 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $1,058.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $862.50 | 2021-2025 | |
| Pfizer INC. | $834.72 | 2019-2025 | |
| Lilly USA, LLC | $744.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $481.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $470.52 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.04 | 2019-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $337.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $325.07 | 2022-2025 | |
| Amgen INC. | $316.66 | 2020-2025 | Repatha, Otezla, Otezla |
| Esperion Therapeutics, INC. | $211.70 | 2021-2025 | Nexletol |
| Abbott Laboratories | $202.79 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.50 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $169.91 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $135.10 | 2019-2022 | |
| Boston Scientific Corporation | $134.74 | 2025 | Watchman Flx, Watchman Access System |
| Paratek Pharmaceuticals, INC. | $88.86 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $86.64 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $83.87 | 2022-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $82.18 | 2020-2022 | |
| Amarin Pharma, INC. | $81.40 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $67.13 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $66.53 | 2024-2025 | |
| Insmed, INC. | $62.49 | 2025 | Brinsupri, Arikayce |
| Eisai INC. | $58.05 | 2020-2022 | |
| Astellas Pharma US INC | $46.95 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $43.12 | 2025 | Voquezna |
| Dexcom, INC. | $38.64 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $37.72 | 2022 | |
| Bausch Health US, LLC | $33.25 | 2020-2021 | |
| Seqirus USA INC | $31.17 | 2024 | Fluad, Flucelvax |
| Medtronic, INC. | $24.74 | 2025 | Inceptiv |
| Otsuka America Pharmaceutical, INC. | $24.48 | 2023 | Rexulti |
| Celgene Corporation | $21.14 | 2025 | Breyanzi |
| Radius Health, INC. | $17.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.28 | 2024 | Eliquis |
| Phadia US INC. | $14.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.